Literature DB >> 18722918

Isolated limb perfusion for melanoma.

Bin B R Kroon1, Eva M Noorda, Bart C Vrouenraets, Gooike W van Slooten, Omgo E Nieweg.   

Abstract

Isolated limb perfusion with high-dose chemotherapy is an accepted treatment modality to achieve locoregional control in advanced melanoma of the extremities. The drug of choice is melphalan. Tumor necrosis factor-alpha is frequently added to melphalan in bulky disease, and this combination may be an option for repeat perfusion for recurrent melanoma after a first perfusion. Results of perfusions performed with tissue temperatures between 37 degrees C and 38 degrees C seem to be equivalent to those of the perfusions performed under mild hyperthermic conditions. Perfusion cannot be recommended as an adjunct to wide local excision in patients who have primary melanoma. Adjuvant perfusion in repeatedly recurrent limb melanoma, however, may be of value because it lengthens the limb recurrence-free interval and decreases the number of lesions per recurrence significantly. Regional toxicity of perfusion should be mild when risk factors are taken into account.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722918     DOI: 10.1016/j.soc.2008.04.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  2 in total

Review 1.  Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.

Authors:  Shuang Cai; Taryn R Bagby; M Laird Forrest
Journal:  Ther Deliv       Date:  2011-11

2.  Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.

Authors:  Heiner Ruschulte; Serena Shi; William W Tseng; Kerstin Kolodzie; Philip C Crawford; Darren B Schneider; Mohammed Kashani-Sabet; David Minor; Christian Apfel; Stanley Pl Leong
Journal:  BMC Anesthesiol       Date:  2013-07-17       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.